Chips · Stock report · Air Liquide (Euronext Paris: AI.PA)
Air Liquide — 2nd of 86 chip-section stocks over one month, with money flow still accelerating
The Closelooknet read
Air Liquide (Euronext Paris: AI.PA) is the second-strongest of the 86 stocks in our chip section over the past month, up 13.2%. The section includes suppliers of gases, chemicals and consumables to chipmakers. It closed at a new 52-week high of €192.84 on 12 November. Our money-flow reading (a gauge of net buying pressure) stands at 3.8 and is accelerating: it is up 1.9 over five sessions and up 3.2 over the past 21 sessions. Our momentum score is 79 of 100, yet the composite is 51, held back by growth (26) and valuation (35). What we watch: whether the stock holds above its 11 November closing high of €192.16 over the coming sessions, or slips back under it.
Where Air Liquide stands among our chip-section stocks
Its one-month rank is 2 of 86, and the three peers we compare it with moved less over the month. Linde (LIN) rose 6.1% and sits 4.4% below its 2 July high. Qnity Electronics (Q) gained 0.9% and is 30.2% below its 22 June high. Ajinomoto (2802.T, Tokyo) fell 19.5% and is 31.0% below its 1 July high. Air Liquide, by contrast, closed at a new 52-week high.
Our money-flow and quality readings
Our money-flow reading is 3.8, labelled accelerating-up. On our scores Air Liquide rates 51 of 100 overall: momentum 79, quality 56, balance sheet 56, cash quality 52. Capital allocation (36), valuation (35) and growth (26) sit below the composite. The Piotroski score is a check of financial health, scored 6 of 9.
Price trend
Air Liquide closed at €192.84 on 12 November, up 0.35% on the day. That is 0.35% above the 52-week closing high of €192.16 set on 11 November. The stock is up 20.3% this year and 13.7% over twelve months. It trades 11.2% above its 50-day average (€173.39) and 10.8% above the average close of the last 200 sessions (€174.10). Its typical daily swing is about 1.1%. The 52-week low close was €155.68 on 20 January.
Closelooknet is a research diary. Nothing here is investment advice or a recommendation to buy or sell.